Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.

Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I.

Clin Colorectal Cancer. 2018 Sep 29. pii: S1533-0028(18)30219-6. doi: 10.1016/j.clcc.2018.09.010. [Epub ahead of print]

PMID:
30404764
2.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]

PMID:
30351999
3.

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032.

Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ.

J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181-2. doi: 10.1016/j.jtho.2018.10.003. [Epub ahead of print]

4.

Synchronous hepatocellular carcinoma and lymphoepithelioma-like carcinoma arising from 2 different sites of the liver: A case report.

Shih EJ, Chau IY, Yeh YC, Chau GY.

Medicine (Baltimore). 2018 Oct;97(40):e12548. doi: 10.1097/MD.0000000000012548.

5.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv238-iv255. doi: 10.1093/annonc/mdy308. No abstract available.

PMID:
30285213
6.

Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.

Athauda A, Watkins D, Mohammed K, Chau I, Starling N, Rao S, Tait D, Aitken K, Cunningham D.

Anticancer Res. 2018 Oct;38(10):5943-5949. doi: 10.21873/anticanres.12940.

PMID:
30275223
7.

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).

Glynne-Jones R, Hall MR, Lopes A, Pearce S, Goh V, Bosompem S, Bridgewater J, Chau I, Wasan H, Moran B, Melcher L, West NP, Quirke P, Wong WL, Beare S, Hava N, Duggan M, Harrison M.

Heliyon. 2018 Sep 22;4(9):e00804. doi: 10.1016/j.heliyon.2018.e00804. eCollection 2018 Sep.

8.

Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?

Cartwright E, Keane FK, Enzinger PC, Hong T, Chau I.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):280-291. doi: 10.1200/EDBK_200785.

9.

Neoadjuvant rectal score: run with the hare and hunt with the hounds.

Sclafani F, Kalaitzaki E, Cunningham D, Tait D, Brown G, Chau I.

Ann Oncol. 2018 Sep 11. doi: 10.1093/annonc/mdy403. [Epub ahead of print] No abstract available.

PMID:
30204839
10.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30.

PMID:
30166348
11.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O'Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M.

Clin Chem. 2018 Nov;64(11):1626-1635. doi: 10.1373/clinchem.2018.289629. Epub 2018 Aug 27.

12.

Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients.

Kühnl A, Cunningham D, Hutka M, Peckitt C, Rozati H, Morano F, Chong I, Gillbanks A, Wotherspoon A, Harris M, Murray T, Chau I.

BMC Hematol. 2018 Aug 14;18:19. doi: 10.1186/s12878-018-0109-0. eCollection 2018.

13.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT.

J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.

14.

HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer.

Lote H, Valeri N, Chau I.

World J Gastrointest Oncol. 2018 Jul 15;10(7):159-171. doi: 10.4251/wjgo.v10.i7.159. Review.

15.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Jun 8. pii: S1533-0028(18)30141-5. doi: 10.1016/j.clcc.2018.05.011. [Epub ahead of print]

16.

Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.

Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8.

PMID:
29980492
17.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
18.

Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response.

Patel UB, Blomqvist L, Chau I, Nicholls J, Brown G.

Colorectal Dis. 2018 May;20 Suppl 1:76-81. doi: 10.1111/codi.14084.

PMID:
29878685
19.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.

Oncologist. 2018 May 31. pii: theoncologist.2018-0044. doi: 10.1634/theoncologist.2018-0044. [Epub ahead of print]

PMID:
29853658
20.

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX.

Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29.

PMID:
29808014
21.

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D.

Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

22.

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, Renni M, Young AM.

Oncologist. 2018 Jul;23(7):822-839. doi: 10.1634/theoncologist.2017-0473. Epub 2018 Apr 12. Review.

PMID:
29650686
23.

Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain.

Senisterra G, Zhu HY, Luo X, Zhang H, Xun G, Lu C, Xiao W, Hajian T, Loppnau P, Chau I, Li F, Allali-Hassani A, Atadja P, Oyang C, Li E, Brown PJ, Arrowsmith CH, Zhao K, Yu Z, Vedadi M.

SLAS Discov. 2018 Oct;23(9):930-940. doi: 10.1177/2472555218766278. Epub 2018 Mar 21.

PMID:
29562800
24.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6. Review.

PMID:
29508762
25.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

26.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

PMID:
29442540
27.

Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.

Davidson M, Chau I.

Expert Rev Anticancer Ther. 2018 Apr;18(4):327-338. doi: 10.1080/14737140.2018.1438271. Epub 2018 Feb 12.

PMID:
29431018
28.

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.

Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N.

Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5.

29.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N.

Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.

PMID:
29361134
30.

Efficacy of intraoperative epidural triamcinolone application in lumbar microdiscectomy: a matched-control study.

Stienen MN, Joswig H, Chau I, Neidert MC, Bellut D, Wälchli T, Schaller K, Gautschi OP.

J Neurosurg Spine. 2018 Mar;28(3):291-299. doi: 10.3171/2017.6.SPINE161372. Epub 2017 Dec 15.

PMID:
29243999
31.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.

PMID:
29188284
32.

Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.

Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Mar;17(1):e69-e76. doi: 10.1016/j.clcc.2017.10.006. Epub 2017 Oct 16.

PMID:
29129559
33.

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.

Gleeson M, Peckitt C, Cunningham D, Gibb A, Hawkes EA, Back M, Yasar B, Foley K, Lee R, Dash J, Johnson H, O'Hara C, Wotherspoon A, Attygalle A, Menasce L, Shenjere P, Potter M, Ethell ME, Dearden C, Radford J, Chau I, Linton K.

Leuk Lymphoma. 2018 Jul;59(7):1586-1595. doi: 10.1080/10428194.2017.1393671. Epub 2017 Nov 9.

PMID:
29119842
34.

Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.

Moorcraft SY, Jones T, Walker BA, Ladas G, Kalaitzaki E, Yuan L, Begum R, Eltahir Z, Wotherspoon A, Montero-Fernandez A, Teixeira Mendes LS, Gonzalez de Castro D, Wilson SH, Proszek P, To YM, Hawkes E, Roy A, Cunningham D, Rao S, Watkins D, Starling N, Bowcock AM, Chau I.

Oncotarget. 2017 Apr 11;8(39):64999-65008. doi: 10.18632/oncotarget.17048. eCollection 2017 Sep 12.

35.

Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?

Chau I.

Lancet. 2017 Dec 2;390(10111):2418-2419. doi: 10.1016/S0140-6736(17)32131-1. Epub 2017 Oct 6. No abstract available.

PMID:
28993053
36.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.

J Gastroenterol Hepatol. 2018 Apr;33(4):814-824. doi: 10.1111/jgh.14007. Epub 2018 Feb 1.

PMID:
28960444
37.

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I.

Ann Oncol. 2017 Dec 1;28(12):2932-2942. doi: 10.1093/annonc/mdx514. Review.

38.

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I.

Br J Cancer. 2017 Nov 7;117(10):1478-1485. doi: 10.1038/bjc.2017.320. Epub 2017 Sep 21.

39.

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.

Davidson M, Chau I, Cunningham D, Khabra K, Iveson T, Hickish T, Seymour M, Starling N.

World J Gastrointest Oncol. 2017 Aug 15;9(8):333-340. doi: 10.4251/wjgo.v9.i8.333.

40.

Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging.

Studer Bruengger AA, Wechalekar K, Khattar R, Rosen SD, Robertus JL, Chau I, Morganstein D, Rosendahl U, Lyon A, Mohiaddin R.

Can J Cardiol. 2017 Oct;33(10):1336.e9-1336.e12. doi: 10.1016/j.cjca.2017.06.007. Epub 2017 Jun 16.

41.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.

Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ.

Gut. 2018 Oct;67(10):1780-1792. doi: 10.1136/gutjnl-2017-314408. Epub 2017 Aug 22.

42.

Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.

Kühnl A, Cunningham D, Chau I.

Cancer Treat Rev. 2017 Sep;59:132-137. doi: 10.1016/j.ctrv.2017.07.009. Epub 2017 Aug 9. Review.

PMID:
28822237
43.

Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.

Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ.

Expert Rev Anticancer Ther. 2017 Oct;17(10):951-964. doi: 10.1080/14737140.2017.1369882. Epub 2017 Aug 28. Review.

PMID:
28817982
44.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.

Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N.

Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8.

45.

Small intestine follicular dendritic cell sarcoma with liver metastasis: A case report.

Chang YC, Chau IY, Yeh YC, Chau GY.

Medicine (Baltimore). 2017 Aug;96(31):e7261. doi: 10.1097/MD.0000000000007261.

46.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H.

J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16.

47.

Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.

Chau I.

Clin Cancer Res. 2017 Oct 15;23(20):6002-6011. doi: 10.1158/1078-0432.CCR-17-0020. Epub 2017 Jun 14. Review.

48.

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Erratum in: Eur J Cancer. 2018 Sep;100:135-136.

PMID:
28591675
49.

Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

Petty RD, Dahle-Smith A, Stevenson DAJ, Osborne A, Massie D, Clark C, Murray GI, Dutton SJ, Roberts C, Chong IY, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk SJ, Elyan S, Garcia-Alonso A, Fyfe DW, Wadsley J, Chau I, Ferry DR, Miedzybrodzka Z.

J Clin Oncol. 2017 Jul 10;35(20):2279-2287. doi: 10.1200/JCO.2016.70.3934. Epub 2017 May 24.

PMID:
28537764
50.

Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma.

Anandappa G, Chau I.

Hematol Oncol Clin North Am. 2017 Jun;31(3):529-544. doi: 10.1016/j.hoc.2017.02.001. Epub 2017 Mar 22. Review.

PMID:
28501092

Supplemental Content

Support Center